For decades, oral delivery of peptides was considered nearly impossible. The harsh acidic environment of the stomach, combined with extensive enzymatic degradation and poor intestinal permeability, meant that only a negligible fraction of orally administered peptides would reach systemic circulation. That landscape is now changing rapidly.
The approval of semaglutide (Rybelsus) as the first oral GLP-1 receptor agonist marked a watershed moment for the field. By co-formulating the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer, researchers achieved clinically meaningful oral bioavailability for a peptide that was previously available only by injection.
SNAC works by creating a localized increase in pH at the gastric epithelium and promoting transient transcellular absorption of the peptide. This approach is specific to the stomach rather than the intestine, which distinguishes it from many other absorption enhancement strategies. The success of this formulation has validated the concept and inspired a wave of research into oral delivery of other peptides.
Enteric coating technology represents another approach to oral peptide delivery. By encapsulating peptides in pH-sensitive polymers that dissolve only in the alkaline environment of the small intestine, researchers can protect the peptide from gastric acid degradation. However, this approach still requires a strategy for overcoming the intestinal epithelial barrier.
Nanoparticle-based delivery systems are among the most actively researched approaches. These systems encapsulate peptides within protective matrices of biodegradable polymers such as PLGA, chitosan, or lipid nanoparticles. The particles can protect the peptide from enzymatic degradation while promoting uptake through intestinal epithelial cells or M-cells in Peyer's patches.
Permeation enhancers beyond SNAC are also under investigation. These include medium-chain fatty acids (such as sodium caprate), cell-penetrating peptides, and bile salt derivatives. Each approach has a different mechanism for temporarily and reversibly increasing intestinal permeability, with varying profiles of efficacy and safety.
Mucoadhesive formulations aim to prolong the contact time between the peptide formulation and the intestinal epithelium. By using polymers that adhere to the mucus layer, these systems can create a concentration gradient that drives peptide absorption over an extended period. Thiolated polymers and lectins are among the materials being investigated for this purpose.
Enzyme inhibitor co-formulations take a different approach by suppressing the proteolytic enzymes that would normally degrade the peptide in the gastrointestinal tract. Protease inhibitors such as aprotinin, bestatin, and bowman-birk inhibitor have been studied in combination with various peptides, though concerns about long-term effects on digestive function remain.
The challenges ahead are substantial but not insurmountable. Achieving reproducible oral bioavailability across diverse patient populations, maintaining peptide stability in commercial formulations with acceptable shelf lives, and scaling manufacturing processes to commercial volumes are all active areas of work.
For the peptide research community, the progress in oral delivery systems represents a potential paradigm shift. If successful, oral formulations could dramatically improve patient compliance, expand the therapeutic applications of peptides, and reduce the barriers to peptide-based treatments. The coming years will be critical in determining which approaches translate from laboratory promise to clinical reality.
